Generic Name and Formulations:
Cycloserine 250mg; caps.
Lilly, Eli and Company
Indications for SEROMYCIN:
In conjunction with other chemotherapy, for the treatment of active pulmonary and extrapulmonary tuberculosis (including renal disease) when the causative organisms are susceptible and when treatment with primary drugs (streptomycin, isoniazid, rifampin, ethambutol) has proved inadequate.
Initially 250mg twice daily at 12-hour intervals for the first 2 weeks. Usual dose: 500mg–1g daily in divided doses monitored by blood levels. Max 1g/day.
Epilepsy. Depression. Severe anxiety. Psychosis. Severe renal insufficiency. Excessive concurrent use of alcohol.
Discontinue or reduce dose if allergic dermatitis or CNS toxicity develops. Ratio of toxic dose to effective dose is small. Monitor blood levels, hematologic, renal, and liver function. Obtain weekly blood levels in patients with reduced renal function, patients receiving >500mg daily dosage, or those showing signs/symptoms suggestive of toxicity. Pregnancy (Cat.C). Nursing mothers: not recommended.
Neurotoxic effects with concomitant ethionamide. Increased risk of epileptic episodes with alcohol. Increased CNS effects with concomitant isoniazid; monitor closely.
CNS effects (eg, convulsions, drowsiness, somnolence, headache, tremor, dysarthria, vertigo, confusion, psychoses, character changes, hyperirritability, aggression, paresis, hyperreflexia, paresthesia, seizures, coma), CHF, allergy, rash, elevated serum transaminase (esp. with preexisting liver disease), anemia (monitor).
Endocrinology Advisor Articles
- FDA Approves Admelog Short-Acting Insulin Lispro Injection
- Fertility Hormone Therapy and Cardiovascular Outcomes: What We Know
- Effects of Peer Influence in Adolescents With Type 1 Diabetes
- More Evidence That Saxagliptin Does Not Increase Risk for AMI in Diabetes
- One-Hour Glucose Readings Predict T2D Risk Better Than 2-Hour Measurements
- FDA: Vitamin B7 May Interfere With Lab Tests for Hormone Levels
- Injected and Oral Medications Equally Safe for Gestational Diabetes
- Adjunctive Dapagliflozin Improves Glycemic Control in T1D
- Estradiol Therapy May Benefit Overall Cognition in Postmenopausal Women
- Stopping Postmenopausal HT May Increase Risk for Cardiac, Stroke Death
- Psychosocial Benefits of a Bihormonal Bionic Pancreas System in T1D
- Safety of Chronic Total Occlusion Percutaneous Coronary Intervention in Diabetes
- Oral Insulin Not a Reliable Preventive Strategy for Type 1 Diabetes
- Prevention of Bone Mineral Density Loss Needed in Epilepsy
- Gastric Bypass Blunts B-Cell Sensitivity During Glycemia